ReviewDigestive diseases and sciences2017
Primary Antibiotic Resistance of Helicobacter pylori in China.
Review in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Antibiotic resistance in Helicobacter pylori among children and adolescents in East Asia: A systematic review and meta-analysis.Chinese medical journal · 2024Pooled it
- Network meta-analysis of treatment interventions forFrontiers in pharmacology · 2024Pooled it
- Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori.BMC gastroenterology · 2024Trial
- Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: A large-scale prospective, multicenter, open-label, randomized controlled study.Helicobacter · 2022Trial
- Application of Visual Gene Clip-Based Tailored Therapy for the Eradication ofBioMed research international · 2021Trial
- Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases.MicrobiologyOpen · 2020Trial
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.Antimicrobial agents and chemotherapy · 2018Trial
- Article
- Characterizing the profile transformation of Helicobacter pylori: increased secondary and multidrug resistance following failed eradication in Ningxia, China.BMC microbiology · 2026Article
- Levofloxacin and Rifampin Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Multiplex fluorescent PCR-based detection of Helicobacter pylori nucleic acid and antibiotic resistance genes in clinical stool samples: a performance evaluation from Gansu Province, China.BMC infectious diseases · 2026Article
- Methodological evaluation ofFrontiers in cellular and infection microbiology · 2026Article
- Comparative molecular profiling of Helicobacter pylori infection and antibiotic genotypic resistance in paired gastric mucosa, gastric juice, and stool samples.Scientific reports · 2025Article
- Overcoming antibiotic-resistantWorld journal of gastroenterology · 2025Review
- Multiplex PCR-Mass Spectrometry Mini-Sequencing Technology Detected Antibiotic Resistance ofInternational journal of molecular sciences · 2025Article
- Article
- Analysis of Helicobacter pylori resistance in patients with different gastric diseases.Scientific reports · 2024Article
- [Comparison of Epsilometer test and agar dilution method in detecting the sensitivity ofBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2023Article
- Furazolidone-induced pulmonary toxicity inWorld journal of clinical cases · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsAntibiotic resistance is the most important factor leading to the failure of eradication regimens; thus, it is important to obtain regional antibiotic resistance information. This review focuses on the prevalence of Helicobacter pylori primary resistance to clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and furazolidone in China.
methodsWe searched the PubMed, EMBASE, the China National Knowledge Infrastructure, and Chinese Biomedical databases from the earliest date of each database to October 2016. The search terms included the following: H. pylori, antibiotic (including clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and furazolidone) resistance with or without China or different regions of China. The data analysis was performed using MedCalc 15.2.2. Each article was weighted according to the number of isolated H. pylori strains. A pooled proportion analysis was performed.
resultsTwenty-three studies (14 studies in English and 9 in Chinese) were included in this review. A total of 6274, 6418, 3921, 5468, 2802, and 275 H. pylori strains were included in this review to evaluate the prevalence of H. pylori primary resistance to clarithromycin, metronidazole, levofloxacin, amoxicillin, tetracycline, and furazolidone, respectively. Overall, the primary resistance rates of clarithromycin, metronidazole, levofloxacin, amoxicillin, tetracycline, and furazolidone were 28.9, 63.8, 28.0, 3.1, 3.9, and 1.7%, respectively.
conclusionsIn China, the prevalence of H. pylori primary resistance to clarithromycin, metronidazole, and levofloxacin was high and increased over time, whereas the resistance rates to amoxicillin, tetracycline, and furazolidone were low and stable over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.